Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Chief Medical Officer | January 14, 2022 | January 18, 2022 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | Director | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kaleido Biosciences, Inc.
Report date January 14, 2022 · Filed January 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 46,800 |
Reported balance
After 2022-01-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-14 · Grant · Acquired 46,800 · Balance 46,800 F1: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2: The restricted stock units shall vest 100% on April 30, 2022 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 125,000 |
Reported balance
After 2022-01-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-14 · Grant · Acquired 125,000 · Balance 125,000 F1: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3: The restricted stock units shall vest on the earlier of 50% on January 14, 2023 and 50% on January 14, 2024 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
F2: The restricted stock units shall vest 100% on April 30, 2022 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer.
F3: The restricted stock units shall vest on the earlier of 50% on January 14, 2023 and 50% on January 14, 2024 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer.
Taysha Gene Therapies, Inc.
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,178 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 21,335 · Balance 127,178 F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2036-06-01 | Direct | 42,671 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 42,671 · Balance 42,671 F2: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
F2: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 42,671 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001891712-26-000002 · form4-06022026_040612.xml · derivative · entry 2 Long Alison S · CIK 0001891712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,671 Underlying: Common Stock · 42,671 shares Expires 2036-06-01 F2 · derivative.exercise_date: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 21,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001891712-26-000002 · form4-06022026_040612.xml · nonDerivative · entry 1 Long Alison S · CIK 0001891712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,178 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 113,246 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-25-015572 · form4-06042025_040604.xml · derivative · entry 2 Long Alison S · CIK 0001891712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,246 Underlying: Common Stock · 113,246 shares Expires 2035-06-02 F2 · derivative.exercise_date: The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 56,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015572 · form4-06042025_040604.xml · nonDerivative · entry 1 Long Alison S · CIK 0001891712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,843 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:18 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 98,440 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001415889-24-015040 · form4-05312024_040508.xml · derivative · entry 2 Long Alison S · CIK 0001891712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,440 Underlying: Common Stock · 98,440 shares Expires 2034-05-29 F2 · derivative.exercise_date: The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:18 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 49,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015040 · form4-05312024_040508.xml · nonDerivative · entry 1 Long Alison S · CIK 0001891712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,220 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:41 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 43,800 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001209191-23-054339 · doc4.xml · derivative · entry 1 Long Alison S · CIK 0001891712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,800 Underlying: Common Stock · 43,800 shares Expires 2033-11-01 F1 · derivative.exercise_date: The shares vest in 36 equal monthly installments commencing on December 1, 2023 such that the shares will be fully vested on November 1, 2026, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 17:15 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantRestricted Stock Units · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003532 · doc4.xml · derivative · entry 2 Long Alison S · CIK 0001891712 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The restricted stock units shall vest on the earlier of 50% on January 14, 2023 and 50% on January 14, 2024 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer. F3 · derivative.expiration_date: The restricted stock units shall vest on the earlier of 50% on January 14, 2023 and 50% on January 14, 2024 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 17:15 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantRestricted Stock Units · Derivative | 46,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003532 · doc4.xml · derivative · entry 1 Long Alison S · CIK 0001891712 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,800 Underlying: Common Stock · 46,800 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units shall vest 100% on April 30, 2022 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer. F2 · derivative.expiration_date: The restricted stock units shall vest 100% on April 30, 2022 provided, however, that the grant shall immediately vest as of the date of any change in control of the issuer. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 17:18 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantRestricted Stock Units · Derivative | 24,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070022 · doc4.xml · derivative · entry 2 Long Alison S · CIK 0001891712 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,350 Underlying: Common Stock · 24,350 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The restricted stock units shall vest 100% on December 15, 2023. F3 · derivative.expiration_date: The restricted stock units shall vest 100% on December 15, 2023. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 17:18 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-21-070022 · doc4.xml · derivative · entry 1 Long Alison S · CIK 0001891712 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-12-14 F1 · derivative.exercise_date: 25% of this option shall vest on December 15, 2022, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.